Search





Search





Markets
/
Stocks
/
crdl
/

Cardiol Therapeutics Inc

CRDL

Add to Watchlist

1.281USD

+0.051+4.16%

Close 07-23 16:00（ET）Quotes delayed by 15 min

143.33MMarket Cap

LossP/E TTM

Cardiol Therapeutics Inc

1.281

+0.051+4.16%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+4.16%

5 Days

+4.16%

1 Month

+22.02%

6 Months

+23.19%

Year to Date

+34.33%

1 Year

-11.03%

Key Figures

1.250Open

1.320High

4.03KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

0.00%Turnover Ratio

1.230Prev. Close

1.215Low

4.74KTurnover

LossP/E Static

8.10P/B

0.00%Div Yield TTM

-127.85%ROA

2.33052wk High

-0.02Volume Ratio

-36.68MNet Profit

111.87MShares

-0.2786EPS TTM

0.50Beta

-173.96%ROE

1.22552wk Low

8.54%Amplitude

--Gross Margin

143.33MMarket Cap

4.82Reward/Risk

4.03%Risk Rate

TradingKey Stock Score of Cardiol Therapeutics Inc

Currency: USD Updated: 2026-07-23

Key Insights

Cardiol Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 139 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cardiol Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

139 / 386

Overall Ranking

214 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Cardiol Therapeutics Inc Highlights

StrengthsRisks

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -4.41, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 25.40M shares, increasing 6.38% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.50.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.333

Target Price

+491.40%

Upside Space

Cardiol Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.333

Target Price

+491.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

495

Total

Median

Average

Company name

Ratings

Analysts

Cardiol Therapeutics Inc

CRDL

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

Insmed Inc

INSM

...

Indicators

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.056

Buy

RSI(14)

60.868

Neutral

STOCH(KDJ)(9,3,3)

79.538

Neutral

ATR(14)

0.093

High Vlolatility

CCI(14)

89.634

Neutral

Williams %R

24.746

Buy

TRIX(12,20)

0.432

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.239

Buy

MA10

1.175

Buy

MA20

1.105

Buy

MA50

1.150

Buy

MA100

1.196

Buy

MA200

1.114

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Cardiol Therapeutics Inc Info

Ticker SymbolCRDL

CompanyCardiol Therapeutics Inc

CEOElsley (David)

Websitehttps://www.cardiolrx.com/

Shareholders

Shareholders

Proportion

MMCAP Asset Management

13.73%

Tejara Capital Ltd.

4.59%

Elsley (David G)

1.20%

Global X Investments Canada Inc.

0.79%

Willner (Michael Jay)

0.78%

Other

78.92%

Popular Instruments

FAQs

What is the current price of Cardiol Therapeutics Inc (CRDL)?



The current price of Cardiol Therapeutics Inc (CRDL) is 1.23.

What is the symbol of Cardiol Therapeutics Inc?



The ticker symbol of Cardiol Therapeutics Inc is CRDL.

What is the 52-week high of Cardiol Therapeutics Inc?



The 52-week high of Cardiol Therapeutics Inc is 2.33.

What is the 52-week low of Cardiol Therapeutics Inc?



The 52-week low of Cardiol Therapeutics Inc is 1.23.

What is the market capitalization of Cardiol Therapeutics Inc?



The market capitalization of Cardiol Therapeutics Inc is 137.60M.

Is Cardiol Therapeutics Inc (CRDL) currently rated as Buy, Hold, or Sell?



According to analysts, Cardiol Therapeutics Inc (CRDL) has an overall rating of Buy, with a price target of 7.33.

What is the Earnings Per Share (EPS TTM) of Cardiol Therapeutics Inc (CRDL)?



The Earnings Per Share (EPS TTM) of Cardiol Therapeutics Inc (CRDL) is -0.28.